The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Dendritic Cell Cancer Vaccine Market Research Report 2024

Global Dendritic Cell Cancer Vaccine Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1413931

No of Pages : 98

Ask Your Query

Synopsis

Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.

The global Dendritic Cell Cancer Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Dendritic Cell Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dendritic Cell Cancer Vaccine.

Report Scope

The Dendritic Cell Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dendritic Cell Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Dendritic Cell Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Activarti
  • Argos Therapeutics
  • SOTIO (Acquired by PPF Group)
  • Bellicum Pharmaceuticals
  • JW CreaGene
  • DanDrit
  • DCPrime
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Immutep Limited
  • Dendreon Corporation
  • Oncobiomed

Segment by Type

  • CreaVax
  • Sipuleucel-T (Provenge)
  • Others

Segment by Application

  • Pediatrics
  • Adults

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dendritic Cell Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dendritic Cell Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Dendritic Cell Cancer Vaccine Market Overview
1.1 Product Overview and Scope of Dendritic Cell Cancer Vaccine
1.2 Dendritic Cell Cancer Vaccine Segment by Type
1.2.1 Global Dendritic Cell Cancer Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 CreaVax
1.2.3 Sipuleucel-T (Provenge)
1.2.4 Others
1.3 Dendritic Cell Cancer Vaccine Segment by Application
1.3.1 Global Dendritic Cell Cancer Vaccine Market Value by Application: (2024-2030)
1.3.2 Pediatrics
1.3.3 Adults
1.4 Global Dendritic Cell Cancer Vaccine Market Size Estimates and Forecasts
1.4.1 Global Dendritic Cell Cancer Vaccine Revenue 2019-2030
1.4.2 Global Dendritic Cell Cancer Vaccine Sales 2019-2030
1.4.3 Global Dendritic Cell Cancer Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Dendritic Cell Cancer Vaccine Market Competition by Manufacturers
2.1 Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Dendritic Cell Cancer Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Dendritic Cell Cancer Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Product Type & Application
2.7 Dendritic Cell Cancer Vaccine Market Competitive Situation and Trends
2.7.1 Dendritic Cell Cancer Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Dendritic Cell Cancer Vaccine Players Market Share by Revenue
2.7.3 Global Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Dendritic Cell Cancer Vaccine Retrospective Market Scenario by Region
3.1 Global Dendritic Cell Cancer Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Dendritic Cell Cancer Vaccine Global Dendritic Cell Cancer Vaccine Sales by Region: 2019-2030
3.2.1 Global Dendritic Cell Cancer Vaccine Sales by Region: 2019-2024
3.2.2 Global Dendritic Cell Cancer Vaccine Sales by Region: 2025-2030
3.3 Global Dendritic Cell Cancer Vaccine Global Dendritic Cell Cancer Vaccine Revenue by Region: 2019-2030
3.3.1 Global Dendritic Cell Cancer Vaccine Revenue by Region: 2019-2024
3.3.2 Global Dendritic Cell Cancer Vaccine Revenue by Region: 2025-2030
3.4 North America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.4.1 North America Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)
3.4.3 North America Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.5.1 Europe Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)
3.5.3 Europe Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.7.1 Latin America Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Dendritic Cell Cancer Vaccine Sales by Type (2019-2030)
4.1.1 Global Dendritic Cell Cancer Vaccine Sales by Type (2019-2024)
4.1.2 Global Dendritic Cell Cancer Vaccine Sales by Type (2025-2030)
4.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Dendritic Cell Cancer Vaccine Revenue by Type (2019-2030)
4.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Type (2019-2024)
4.2.2 Global Dendritic Cell Cancer Vaccine Revenue by Type (2025-2030)
4.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Dendritic Cell Cancer Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Dendritic Cell Cancer Vaccine Sales by Application (2019-2030)
5.1.1 Global Dendritic Cell Cancer Vaccine Sales by Application (2019-2024)
5.1.2 Global Dendritic Cell Cancer Vaccine Sales by Application (2025-2030)
5.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Dendritic Cell Cancer Vaccine Revenue by Application (2019-2030)
5.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Application (2019-2024)
5.2.2 Global Dendritic Cell Cancer Vaccine Revenue by Application (2025-2030)
5.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Dendritic Cell Cancer Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Activarti
6.1.1 Activarti Corporation Information
6.1.2 Activarti Description and Business Overview
6.1.3 Activarti Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Activarti Dendritic Cell Cancer Vaccine Product Portfolio
6.1.5 Activarti Recent Developments/Updates
6.2 Argos Therapeutics
6.2.1 Argos Therapeutics Corporation Information
6.2.2 Argos Therapeutics Description and Business Overview
6.2.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Argos Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.2.5 Argos Therapeutics Recent Developments/Updates
6.3 SOTIO (Acquired by PPF Group)
6.3.1 SOTIO (Acquired by PPF Group) Corporation Information
6.3.2 SOTIO (Acquired by PPF Group) Description and Business Overview
6.3.3 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product Portfolio
6.3.5 SOTIO (Acquired by PPF Group) Recent Developments/Updates
6.4 Bellicum Pharmaceuticals
6.4.1 Bellicum Pharmaceuticals Corporation Information
6.4.2 Bellicum Pharmaceuticals Description and Business Overview
6.4.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product Portfolio
6.4.5 Bellicum Pharmaceuticals Recent Developments/Updates
6.5 JW CreaGene
6.5.1 JW CreaGene Corporation Information
6.5.2 JW CreaGene Description and Business Overview
6.5.3 JW CreaGene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 JW CreaGene Dendritic Cell Cancer Vaccine Product Portfolio
6.5.5 JW CreaGene Recent Developments/Updates
6.6 DanDrit
6.6.1 DanDrit Corporation Information
6.6.2 DanDrit Description and Business Overview
6.6.3 DanDrit Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 DanDrit Dendritic Cell Cancer Vaccine Product Portfolio
6.6.5 DanDrit Recent Developments/Updates
6.7 DCPrime
6.6.1 DCPrime Corporation Information
6.6.2 DCPrime Description and Business Overview
6.6.3 DCPrime Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 DCPrime Dendritic Cell Cancer Vaccine Product Portfolio
6.7.5 DCPrime Recent Developments/Updates
6.8 Elios Therapeutics
6.8.1 Elios Therapeutics Corporation Information
6.8.2 Elios Therapeutics Description and Business Overview
6.8.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Elios Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.8.5 Elios Therapeutics Recent Developments/Updates
6.9 ImmunoCellular Therapeutics
6.9.1 ImmunoCellular Therapeutics Corporation Information
6.9.2 ImmunoCellular Therapeutics Description and Business Overview
6.9.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.9.5 ImmunoCellular Therapeutics Recent Developments/Updates
6.10 Kiromic
6.10.1 Kiromic Corporation Information
6.10.2 Kiromic Description and Business Overview
6.10.3 Kiromic Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Kiromic Dendritic Cell Cancer Vaccine Product Portfolio
6.10.5 Kiromic Recent Developments/Updates
6.11 Medigene
6.11.1 Medigene Corporation Information
6.11.2 Medigene Dendritic Cell Cancer Vaccine Description and Business Overview
6.11.3 Medigene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Medigene Dendritic Cell Cancer Vaccine Product Portfolio
6.11.5 Medigene Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck Dendritic Cell Cancer Vaccine Description and Business Overview
6.12.3 Merck Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Merck Dendritic Cell Cancer Vaccine Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Northwest Biotherapeutics
6.13.1 Northwest Biotherapeutics Corporation Information
6.13.2 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Description and Business Overview
6.13.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.13.5 Northwest Biotherapeutics Recent Developments/Updates
6.14 Immutep Limited
6.14.1 Immutep Limited Corporation Information
6.14.2 Immutep Limited Dendritic Cell Cancer Vaccine Description and Business Overview
6.14.3 Immutep Limited Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Immutep Limited Dendritic Cell Cancer Vaccine Product Portfolio
6.14.5 Immutep Limited Recent Developments/Updates
6.15 Dendreon Corporation
6.15.1 Dendreon Corporation Corporation Information
6.15.2 Dendreon Corporation Dendritic Cell Cancer Vaccine Description and Business Overview
6.15.3 Dendreon Corporation Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Dendreon Corporation Dendritic Cell Cancer Vaccine Product Portfolio
6.15.5 Dendreon Corporation Recent Developments/Updates
6.16 Oncobiomed
6.16.1 Oncobiomed Corporation Information
6.16.2 Oncobiomed Dendritic Cell Cancer Vaccine Description and Business Overview
6.16.3 Oncobiomed Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Oncobiomed Dendritic Cell Cancer Vaccine Product Portfolio
6.16.5 Oncobiomed Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dendritic Cell Cancer Vaccine Industry Chain Analysis
7.2 Dendritic Cell Cancer Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dendritic Cell Cancer Vaccine Production Mode & Process
7.4 Dendritic Cell Cancer Vaccine Sales and Marketing
7.4.1 Dendritic Cell Cancer Vaccine Sales Channels
7.4.2 Dendritic Cell Cancer Vaccine Distributors
7.5 Dendritic Cell Cancer Vaccine Customers
8 Dendritic Cell Cancer Vaccine Market Dynamics
8.1 Dendritic Cell Cancer Vaccine Industry Trends
8.2 Dendritic Cell Cancer Vaccine Market Drivers
8.3 Dendritic Cell Cancer Vaccine Market Challenges
8.4 Dendritic Cell Cancer Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock